MPN Hub’s Post

Cytokine Release Syndrome (CRS) is an overreaction of the immune system caused by excessive, prolonged cytokine production. CRS can be triggered by a wide range of indications, including modern immunotherapies such as CAR T-cell therapy and Bispecific Antibodies. CytoAgents' lead drug candidate, CTO1681, reduces the cytokines generated during CAR T-cell therapy while enabling the body to maintain appropriate cytokine levels. Reducing the rates and severity of toxicity allows for the treatment of more patients, treatment in the outpatient setting, and the decrease of treatment-related morbidity. Learn more about CRS and CTO1681 from the link in the comments. #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

Here is an example of how we used ImitateDb (https://lnkd.in/gaWmRHxb) to study how mimicry in SARS-CoV-2 is responsible for cardiovascular effects. https://lnkd.in/gybVBPJr ImitateDb now has a updated mimicry data for SARS-CoV-2 (https://lnkd.in/gHjjSNhs)

Promising new treatment strategy for aggressive form of leukaemia - Pf Media https://bit.ly/4463eb5

Source: Blood This study examines the impact of free light chain mass spectrometry (FLC-MS) in AL amyloidosis. FLC-MS is a more sensitive assay that can detect residual disease. The study found that FLC-MS negativity after treatment was associated with better overall survival and organ response rates. FLC-MS assessment could become a new standard for response assessment in AL amyloidosis.

Remarquable first CRISPR-based gene therapy approval Casgevy was approved for use in the treatment of sickle cell disease on December 8, 2023 and became the first medicine available in the United States to treat a genetic disease using the CRISPR gene-editing technique. Casgevy was approved for use in the treatment of transfusion-dependent beta thalassemia on January 16, 2024. If I remember correctly, that means only 6 years between the first CTA submitted by CRSP (Dec 07, 2017) and the approval. Again, Nucleic Acid Therapeutics are successful.

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

CRISPR-based medicine utilizes the CRISPR-Cas9 gene-editing technology to treat or prevent genetic disorders. Cas9, an enzyme, is guided by RNA molecules to target specific DNA sequences, allowing precise modification. Potential applications include correcting mutations, enhancing immune responses, and developing personalized therapies. Clinical trials are ongoing for conditions like sickle cell anemia and certain types of cancers. Ethical considerations surround the technology, requiring careful regulation and consideration of long-term effects. Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises. Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology. Patients’ hematopoietic (blood) stem cells are modified by genome editing using CRISPR/Cas9 technology.

https://lnkd.in/dXZuQk9Y We studied body composition measures (BCM), to identify patients at higher risk for severe alpelisib related hyperglycemia, and cutaneous toxicity. Our findings suggest the potential use of BCM to caution toxicity risk, allowing for personalized therapeutic observation and intervention.

Further investigation of tamoxifen as a treatment option in patients with #MPNs with extra consideration for thrombotic risk is supported by results of a phase 2 study. #MPNSM https://lnkd.in/efpxPw3M #MPNresearch #MyeloproliferativeNeoplasms #JAK2 #CALR #CancerResearch #ClinicalTrials